clinicaladvisor.com11d
Mirikizumab in Crohn Disease: Insights From the VIVID-1 and VIVID-2 Trials
Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...
pharmaphorum2d
Second trial opens door for Lilly's mirikizumab in ulcerative colitis
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...
pharmaphorum1y
FDA won’t approve Lilly’s mirikizumab for ulcerative colitis
The FDA has issued a complete response letter to Eli Lilly, turning down its attempt to get approval for anti-IL-23p19 antibody mirikizumab as a treatment for ulcerative colitis (UC). The company ...
Pharmabiz1mon
Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh ...
Medindia1mon
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
1 About Omvoh®Omvoh® (mirikizumab-mkrz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults.
Pharmabiz1mon
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...